Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity

Vickie R. Shannon, Ronald Anderson, Ada Blidner, Jennifer Choi, Tim Cooksley, Michael Dougan, Ilya Glezerman, Pamela Ginex, Monica Girotra, Dipti Gupta, Douglas B. Johnson, Maria E. Suarez-Almazor, Bernardo L. Rapoport*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

The immune checkpoints associated with the CTLA-4 and PD-1 pathways are critical modulators of immune activation. These pathways dampen the immune response by providing brakes on activated T cells, thereby ensuring more uniform and controlled immune reactions and avoiding immune hyper-responsiveness and autoimmunity. Cancer cells often exploit these regulatory controls through a variety of immune subversion mechanisms, which facilitate immune escape and tumor survival. Immune checkpoint inhibitors (ICI) effectively block negative regulatory signals, thereby augmenting immune attack and tumor killing. This process is a double-edged sword in which release of regulatory controls is felt to be responsible for both the therapeutic efficacy of ICI therapy and the driver of immune-related adverse events (IrAEs). These adverse immune reactions are common, typically low-grade and may affect virtually every organ system. In the early clinical trials, lung IrAEs were rarely described. However, with ever-expanding clinical applications and more complex ICI-containing regimens, lung events, in particular, pneumonitis, have become increasingly recognized. ICI-related lung injury is clinically distinct from other types of lung toxicity and may lead to death in advanced stage disease. Thus, knowledge regarding the key characteristics and optimal treatment of lung-IrAEs is critical to good outcomes. This review provides an overview of lung-IrAEs, including risk factors and epidemiology, as well as clinical, radiologic, and histopathologic features of ICI-related lung injury. Management principles for ICI-related lung injury, including current consensus on steroid refractory pneumonitis and the use of other immune modulating agents in this setting are also highlighted.

Original languageEnglish (US)
JournalSupportive Care in Cancer
DOIs
StateAccepted/In press - 2020

Keywords

  • Cancer
  • Drug toxicity
  • Drug-induced pneumonitis
  • Immune checkpoint inhibitors
  • Immune-related adverse events (IrAEs)
  • Immunotherapy

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity'. Together they form a unique fingerprint.

  • Cite this

    Shannon, V. R., Anderson, R., Blidner, A., Choi, J., Cooksley, T., Dougan, M., Glezerman, I., Ginex, P., Girotra, M., Gupta, D., Johnson, D. B., Suarez-Almazor, M. E., & Rapoport, B. L. (Accepted/In press). Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. Supportive Care in Cancer. https://doi.org/10.1007/s00520-020-05708-2